View Older Stories View More Recent Stories

Jun 12, 2021 07:02AM IMBRUVICA® (ibrutinib) Plus VENCLEXTA®/VENCLYXTO® (venetoclax) Combination Shows Superior Progression-Free Survival Compared to Chlorambucil Plus Obinutuzumab in First-line Chronic Lymphocytic Leuk
Jun 11, 2021 01:03AM New Data Shows AbbVie's VENCLYXTO®/VENCLEXTA® Fixed Duration Combination Demonstrates Sustained Progression-Free Survival in Chronic Lymphocytic Leukemia Patients after Three Years off Treatment
Jun 8, 2021 08:45AM Allergan Aesthetics and BOTOX® Cosmetic (onabotulinumtoxinA) Put Real Stories at the Forefront in New Campaign
Jun 7, 2021 11:32AM AbbVie (ABBV) CAPTIVATE Study Shows an IMBRUVICA Plus VENCLEXTA/VENCLYXTO Chemotherapy-Free Combination Has Potential to Provide Remission After Fixed-Duration Treatment for CLL
Jun 7, 2021 11:30AM CAPTIVATE Study Shows an IMBRUVICA® (ibrutinib) Plus VENCLEXTA®/VENCLYXTO® (venetoclax) Chemotherapy-Free Combination Has Potential to Provide Remission After Fixed-Duration Treatment for Chronic L
Jun 4, 2021 09:03AM AbbVie (ABBV) Results from IMBRUVICA® (ibrutinib) RESONATE-2 Study Provide Up to Seven Years of PF and OS Data in First-Line CLL
Jun 4, 2021 09:00AM Results from IMBRUVICA® (ibrutinib) RESONATE-2 Study Provide Up to Seven Years of Progression-Free and Overall Survival Data in First-Line Chronic Lymphocytic Leukemia (CLL)
Jun 2, 2021 08:30AM AbbVie to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference
Jun 2, 2021 08:04AM AbbVie (ABBV) Phase 3 Maintenance Results of risankizumab 360 mg achieved the co-primary endpoints
Jun 2, 2021 08:00AM Phase 3 Maintenance Results Show Patients with Crohn's Disease Receiving Risankizumab (SKYRIZI®) Achieved Endoscopic Response and Clinical Remission at One Year
Jun 2, 2021 07:30AM AbbVie to Present Analysis Evaluating Continuous RINVOQ® (upadacitinib) Treatment in Psoriatic Arthritis for More Than One Year at EULAR 2021 Virtual Congress
Jun 2, 2021 07:05AM AbbVie (ABBV) Announces New Long-Term Efficacy and Safety Analyses Evaluating RINVOQ in Patients with Rheumatoid Arthritis to be Presented at EULAR 2021 Virtual Congress
Jun 2, 2021 07:00AM New Long-Term Efficacy and Safety Analyses Evaluating RINVOQ® (upadacitinib) in Patients with Rheumatoid Arthritis to be Presented at EULAR 2021 Virtual Congress
May 26, 2021 08:15AM AbbVie to Present at Bernstein's 37th Annual Strategic Decisions Conference
May 26, 2021 08:00AM AbbVie to Present Data from its Leading Migraine Portfolio at the 2021 American Headache Society (AHS) Annual Scientific Meeting
May 25, 2021 08:01AM AbbVie (ABBV) Receives EC Approval of VENCLYXTO in Combination with Hypomethylating Agent for Patients with Newly Diagnosed Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy
May 25, 2021 08:00AM AbbVie Receives European Commission Approval of VENCLYXTO® (venetoclax) in Combination with a Hypomethylating Agent for Patients with Newly Diagnosed Acute Myeloid Leukemia Who Are Ineligible for Int
May 25, 2021 08:00AM AbbVie Showcases the Depth of its Rheumatology Portfolio with New Data Presented at the EULAR 2021 Virtual Congress of Rheumatology
May 24, 2021 09:16AM AbbVie (ABBV) Presents New Late-Breaking Data Analyses Showing Risankizumab Achieves Clinical Remission and Endoscopic Response at Week 12 in Patients with Moderate to Severe Crohn's Disease
May 24, 2021 09:15AM AbbVie Presents New Late-Breaking Data Analyses Showing Risankizumab (SKYRIZI®) Achieves Clinical Remission and Endoscopic Response at Week 12 in Patients with Moderate to Severe Crohn's Disease
May 24, 2021 08:45AM AbbVie (ABBV) Announces Lancet Publishes Results from Pivotal Global Phase 3 Program Evaluating RINVOQ in Atopic Dermatitis
May 24, 2021 08:45AM The Lancet Publishes Results from Pivotal Global Phase 3 Program Evaluating RINVOQ® (upadacitinib) in Atopic Dermatitis
May 20, 2021 08:00AM AbbVie to Present at the UBS Global Healthcare Virtual Conference
May 19, 2021 08:00AM AbbVie to Showcase Breadth of Oncology Portfolio and Pipeline at the 2021 ASCO and EHA Annual Congresses
May 12, 2021 08:00AM AbbVie to Present at the RBC Capital Markets Global Healthcare Conference
May 10, 2021 08:35AM AbbVie's (ABBV) Allergan Aesthetics to Acquire Soliton (SOLY)
May 10, 2021 08:30AM Allergan Aesthetics to Acquire Soliton, Expanding Body Contouring Portfolio
May 10, 2021 08:30AM Allergan Aesthetics to Acquire Soliton, Expanding Body Contouring Portfolio
Apr 30, 2021 07:42AM AbbVie Reports First-Quarter 2021 Financial Results
Apr 27, 2021 08:30AM Allergan, an AbbVie Company, to Share New Data Highlighting Latest Advancements in Eye Care at ARVO (Association for Research in Vision and Ophthalmology) 2021 Annual Virtual Meeting
Apr 23, 2021 08:04AM AbbVie (ABBV) Receives Positive CHMP Opinion for VENCLYXTO as Combination Regimen for Adult Patients with Newly Diagnosed Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy
Apr 23, 2021 08:00AM AbbVie Receives Positive CHMP Opinion for VENCLYXTO® (venetoclax) as a Combination Regimen for Adult Patients with Newly Diagnosed Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy
Apr 7, 2021 09:01AM AbbVie (ABBV) Submits Regulatory Applications for SKYRIZI (risankizumab) in Psoriatic Arthritis to FDA and EMA
Apr 7, 2021 09:01AM AbbVie Submits Regulatory Applications for SKYRIZI® (risankizumab) in Psoriatic Arthritis to FDA and EMA
Apr 7, 2021 08:00AM AbbVie to Present Data Across its Robust Neuroscience Portfolio at the 2021 American Academy of Neurology (AAN) Annual Meeting
Apr 5, 2021 06:19AM AbbVie (ABBV) Announces Extension of Review for sNDA of Upadacitinib for Treatment of Moderate to Severe Atopic Dermatitis
Apr 2, 2021 05:18PM AbbVie Announces Extension of Review for Supplemental New Drug Application of Upadacitinib for the Treatment of Moderate to Severe Atopic Dermatitis
Apr 1, 2021 08:45AM SkinMedica® Launches Neck Correct Cream for Neck and Décolleté
Apr 1, 2021 08:31AM AbbVie (ABBV) Announces NEJM Publishes 24-Week Results from Phase 3 Study Evaluating RINVOQ in Psoriatic Arthritis
Apr 1, 2021 08:31AM New England Journal of Medicine Publishes 24-Week Results from Phase 3 Study Evaluating RINVOQ™ (upadacitinib) in Psoriatic Arthritis
Mar 31, 2021 08:00AM AbbVie to Host First-Quarter 2021 Earnings Conference Call
Mar 30, 2021 08:01AM AbbVie (ABBV) Announces U.S. FDA Accepts its NDA for Atogepant for the Preventive Treatment of Migraine
Mar 30, 2021 08:00AM U.S. FDA Accepts AbbVie's New Drug Application for Atogepant for the Preventive Treatment of Migraine
Mar 17, 2021 09:11AM AbbVie (ABBV) Announces Extension of Review for sNDA of Upadacitinib for Treatment of Adults with Active Psoriatic Arthritis
Mar 17, 2021 08:45AM AbbVie Announces Extension of Review for Supplemental New Drug Application of Upadacitinib for the Treatment of Adults with Active Psoriatic Arthritis
Feb 25, 2021 08:59AM AbbVie's (ABBV) Allergan Submits NDA to FDA for AGN-190584 to Treat Presbyopia
Feb 25, 2021 08:00AM Allergan, an AbbVie Company, Submits New Drug Application for Investigational AGN-190584 for the Treatment of Presbyopia
Feb 24, 2021 07:14PM HUMIRA® (adalimumab) Receives FDA Approval to Treat Pediatric Patients Living with Moderately to Severely Active Ulcerative Colitis
Feb 23, 2021 08:30AM New REFRESH® DIGITAL Lubricant Eye Drops Tackle Eye Dryness Due to Everyday Screen Use
Feb 22, 2021 08:46AM AbbVie (ABBV) Says Second Phase 3 Induction Study Confirms Upadacitinib Improved Clinical, Endoscopic and Histologic Outcomes in Ulcerative Colitis Patients
View More Recent Stories View Older Stories